Lifevantage Co. Logo
US53222K2050
A1420J
LFVN

Lifevantage Co.

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 6,36 € (+46,21 %). Medianen er 6,36 € (+46,21 %).

Køb
  1
Behold
  2
Sælg
  0

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • LifeVantage misses Q4 forecasts — revenue falls sharply, shares tumble

    LifeVantage reported a 23.1% decline in Q4 revenue to $42.4 million and adjusted EPS of $0.11 (expectation $0.13). The stock fell in regular trading and slipped further after hours after revenue and earnings came in below estimates. New CEO Terrence Moorehead announced a turnaround plan focused on branding, digital strategy and customer retention; no formal guidance was given for 2027. » Mere på de.investing.com


  • Lifevantage to release quarterly results for period ended June 30, 2026, on August 27, 2026

    Lifevantage will present results for the quarter ended June 30, 2026, on August 27, 2026. Two analysts expect on average earnings of $0.115 per share versus $0.150 in the year-ago quarter and revenue of about $44.0 million (‑20.2% versus $55.1 million). For the past fiscal year estimates are $0.560 earnings per share and $184.2 million in revenue, after $0.750 and $228.5 million in the prior year. » Mere på finanzen.net


  • LifeVantage declares quarterly cash dividend of $0.05

    The board of directors of LifeVantage has declared a quarterly cash dividend of $0.05 per common share. Payment will be made on September 15, 2026 to shareholders of record at the close of business on September 1, 2026. The company sells health and wellness products through independent consultants. » Mere på de.investing.com


  • LifeVantage appoints Terrence Moorehead as CEO

    LifeVantage announces the appointment of Terrence Moorehead as president and chief executive officer and as a member of the board of directors effective August 5, 2026. The change follows a 68.6% drop in the share price over the past year; the stock is at $4.57 and market capitalization is $58.4 million. Steve Fife will resign on April 30, 2026; Michael Beindorff will serve as interim CEO until Moorehead assumes his duties after fulfilling contractual obligations with his previous employer. Moorehead was previously CEO of Nature’s Sunshine, where he increased revenue by 45% and EBITDA by 190%; valuation metrics suggest potential undervaluation (P/E 7.43, gross margin 78.75%). » Mere på de.investing.com


  • LifeVantage plans to enter Portuguese market in May 2026

    LifeVantage announced it will introduce its products and direct-selling model with independent consultants in Portugal in May 2026. At launch it will offer Protandim Nrf2 Synergizer, Protandim Nrf1 Synergizer and TrueScience Liquid Collagen, as well as product bundles such as Healthy Glow Essentials. The market entry will use the “Evolve” compensation plan; the company plans to roll out additional products gradually. LifeVantage said the expansion supports international growth, while revenue has recently declined slightly and the stock fell sharply last year, although the company maintains a high gross margin. » Mere på de.investing.com

I 2026 har Lifevantage Co. allerede udloddet 0,13 € i udbytte. Den seneste udlodning fandt sted i september.

Virksomhedstal

I det seneste kvartal havde Lifevantage Co. en omsætning på 32,77 mio. € og et nettoresultat på -173,04 t €
(EUR) september 2026
YoY
Omsætning 32,77 mio. 19,15 %
Bruttofortjeneste 24,69 mio. 23,37 %
Nettoresultat -173,04 t 109,42 %
EBITDA 482,04 t 80,16 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
57,31 mio. €
Antal aktier
12,68 mio.
Højeste/laveste i 52 uger
10,65 € - 3,55 €
Udbytteafkast
3,78 %
Udbytte TTM
0,16 €
Næste udbytte
0,0455 €
Beta
0,74
P/E (PE Ratio)
23,19
PEG (PEG Ratio)
-0,31
K/I (PB Ratio)
1,86
P/S (PS Ratio)
0,37

Virksomhedsprofil

LifeVantage Corporation beskæftiger sig med identifikation, forskning, udvikling, formulering, salg og distribution af nutrigenomiske aktivatorer, kosttilskud, nootropika, pre- og probiotika, vægtkontrolprodukter, hud- og hårplejeprodukter, bade- og kropsprodukter samt målrettede lindringsprodukter. Virksomheden tilbyder Protandim, en serie videnskabeligt validerede kosttilskud; LifeVantage Omega+, et kosttilskud, der kombinerer DHA- og EPA-omega-3-fedtsyrer, omega-7-fedtsyrer og D3-vitamin; LifeVantage ProBio, et kosttilskud til støtte for fordøjelsessystemets sundhed; en serie vægtkontrolprodukter under mærket PhysIQ; Petandim for Dogs, et kosttilskud til bekæmpelse af oxidativt stress hos hunde; og Axio, en serie energidrikspulver. Virksomheden tilbyder desuden anti-aging hudplejeprodukter, herunder ansigtsrensere, perfektionerende lotioner, øjenserummer, anti-aging-cremer, håndcremer og skønhedsserum samt hårplejeprodukter, såsom opkvikkende shampooer, plejende conditionere og hovedbundsserummer under varemærket LifeVantage TrueScience. Derudover tilbyder virksomheden bade- og kropsprodukter samt målrettede lindringsprodukter, såsom bodylotion, bodywash, bodybutter, deodorant, beroligende balsam og kropsmassageolie under varemærket TrueScience. Virksomheden sælger sine produkter via sin hjemmeside samt gennem et netværk af uafhængige distributører i USA, Mexico, Japan, Australien, Hongkong, Canada, Thailand, Storbritannien, Holland, Tyskland, Taiwan, Østrig, Spanien, Irland, Belgien, New Zealand, Singapore og Kina. LifeVantage Corporation har hovedkontor i Lehi, Utah.

Navn
Lifevantage Co.
CEO
Terrence Moorehead
Hjemsted Lehi, ut
USA
Websted
Sektor
Materialer
Branche
Kemikalier
Børsnotering
07.04.1994
Medarbejdere 216

Tickersymboler

Børs Symbol
NASDAQ
LFVN
Frankfurt
L2T1.F
🍪

Parqet  bruger cookies. Læs mere